David Klonoff, MD, is a clinical-investigator at Sutter Health.
Sutter Health Research Enterprise
1720 El Camino Real
, CA, 94010
(650) 697-4345
KlonofD@sutterhealth.org
Primary Research Interests
Related Clinical Trials
CNOGA 005
User Evaluation of the Invasive Component of the CNOGA TensorTip COMBO GLUCOMETER (CoG)
Investigator: David Klonoff MD
Status: Active, Not Recruiting
Diasome DP 01-2019-01
Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec
Investigator: David Klonoff MD
Status: Active, Recruiting
Finesse
Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients
Investigator: David Klonoff MD
Status: Completed
Lexicon 309
Efficacy, Safety & Tolerability of LX4211 as Adjunct Therapy in Adult Patients w/Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control w/Insulin Therapy
Investigator: David Klonoff MD
Status: Completed
Mylan’s Insulin Aspart
Multicenter, Open-Label, Parallel-Group Clinical Study Comparing the Safety and Efficacy of MYL-1601D with NovoLog® in Type 1 Diabetes Mellitus Patients
Investigator: David Klonoff MD
Status: Active, Recruiting
Novo Nordisk- SELECT
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT)
Investigator: David Klonoff MD
Status: Active, Recruiting
ORA-D-007
Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus
Investigator: David Klonoff MD
Status: Completed
Oramed ORA-D-015
A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus
Investigator: David Klonoff MD
Status: Active, Not Recruiting